Creative Medical Technology Holdings, Inc.
CELZ Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$0.69
KIRA · Stoqly’s AI analyst, in plain words
- Creative Medical Technology Holdings, Inc. had $0.0M of revenue in fiscal 2025, down 45.5% on the year before. Over five years, revenue changed −48.4% a year on average.
- Its operating margin was −102,380.0%, down 50,162.7 pts: of every 100 in sales, about −102,380 is left after running the business.
- Creative Medical Technology Holdings, Inc. lost $6.0M in fiscal 2025.
- Creative Medical Technology Holdings, Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 61.0%.
Market cap
$2.6M
P/E
—
Revenue
$0.0M
Net income
−$6.0M
Free cash flow
—
Operating margin
−102,380.0%
Creative Medical Technology Holdings, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−45.5%
No. Sales fell 45.5% last year.
Does it make a profit?
−99,916.7%
No. It lost money last year.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Creative Medical Technology Holdings, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 20, 2026
- Legal name
- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
- CIK
- 0001187953
Creative Medical Technology Holdings, Inc. · CELZ
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.1M | $0.1M | $0.0M | $0.0M | $0.0M |
| Revenue growth | −46.6% | 0.9% | −89.8% | 22.2% | −45.5% |
| Net interest income | $0.0M | — | — | — | — |
| Gross margin | 45.3% | 67.8% | 60.0% | 60.0% | 63.3% |
| Operating margin | −3,560.3% | −11,562.5% | −62,445.6% | −52,217.3% | −102,380.0% |
| Net income | $19.2M | −$10.1M | −$5.3M | −$5.5M | −$6.0M |
| Net margin | 21,881.3% | −11,449.2% | −58,740.0% | −49,940.9% | −99,916.7% |
| Diluted EPS | $5.61 | −$0.93 | −$3.76 | −$3.71 | −$2.52 |
| Cash | |||||
| Cash from operations | −$2.2M | −$7.8M | −$8.0M | −$5.3M | −$5.9M |
| Share buybacks | — | $0.0M | $0.3M | $0.2M | $0.0M |
| Share count change | −98.9% | 236.5% | −87.1% | 5.2% | 61.0% |
| Debt and strength | |||||
| Cash and short-term investments | $10.7M | $8.3M | $3.5M | $5.9M | $7.2M |
| Shareholders' equity | $10.2M | $15.9M | $10.3M | $6.3M | $7.5M |
| Current ratio | 10.2x | 5.6x | 27.7x | 18.7x | 26.0x |
| Interest coverage | −0.7x | — | — | — | — |
| Returns and quality | |||||
| Return on equity | — | −77.8% | −40.3% | −65.8% | −86.5% |
| Return on tangible equity | 198.3% | −65.7% | −53.4% | −94.5% | −84.3% |
| Piotroski F-score | 4 | 2 | 3 | 2 | 4 |
| Altman Z'' | 1.4 | −2.4 | 13.8 | −11.3 | −1.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Creative Medical Technology Holdings, Inc. · CELZ
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.69 a share, the company is worth $2.6M.
Source: SEC EDGAR XBRL filings (CIK 0001187953). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.